ReviewJournal of virology2026
Structural overview of lyssavirus glycoproteins, antibodies, and receptors.
Review in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rabies virus is the most lethal virus ever discovered and remains a global health threat despite vaccines and post-exposure treatment. In addition to rabies, there are also 17 other lyssaviruses, several of which have already crossed species barriers to infect humans and cause the same clinical disease as the rabies virus. While effective in preventing rabies infection, current rabies vaccines do not provide long-lasting protection or elicit antibodies that are broadly protective against both rabies and related lyssaviruses. Efforts to improve rabies vaccines to elicit a uniform, longer-lasting, and more broadly neutralizing antibody response would benefit from structure-guided design, where high-resolution protein structures are used to engineer vaccine antigens. In the last 6 years, the first high-resolution structures of lyssavirus glycoproteins have become available, giving new insights into how these viruses interact with host antibodies and receptors, and making structure-guided antigen design feasible. This review encompasses recent findings in lyssavirus glycoprotein structure, interactions with neutralizing antibodies, and interactions with potential cellular receptors, with an emphasis on the rabies virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.